SPRY (ARS Corp) Market Value

The ARS Pharmaceuticals (SPRY) price chart illustrates the quotes of a company whose revenues rely on the sales expansion of a nasal allergy treatment, where the current figure stands at 0.36. Business prospects depend on the scaling of Neffy, prescription volumes, and margins. Complex certifications and patents serve as a defense against competitors, ensuring the product's integration into emergency medical protocols.

SPRY (ARS Pharmaceuticals, Inc.) Market Value history from 04/28/2023 to 11/11/2026

Comprehensive metric breakdowns and analytics for ARS Corp (SPRY)

- market price and analyst price targets:

Price Chart ARS Pharmaceuticals, Inc.|SPRY - Forecast Levels Chart

- business market valuation indicators:

Market Value ARS Corp|SPRY - Value Adjusted for Debt and Cash

- book value of equity indicators:

Accounting Value per Share ARS Pharmaceuticals|SPRY - Total Stockholders' Equity|Market Value to Book Value Ratio ars-pharma.com|SPRY - Total Asset Value of Company

- debt and solvency information:

- net income and valuation multiples indicators:

SPRY - Net Profit|Future Profit ARS Pharmaceuticals|SPRY - Company Value to Net Income|Future Price to Earnings ARS Pharma|SPRY - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio ARS Corp|SPRY - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) ARS Pharmaceuticals|SPRY - Earnings per share for the trailing year|Quarterly EPS earnings growth ars-pharma.com|SPRY - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year ARS Pharmaceuticals

Fundamental company analysis:SPRY (ARS Pharmaceuticals, Inc.)

Investors are assessing the potential of ARS Pharmaceuticals (SPRY) through its market capitalization, calculated as the product of the current share price and the total number of outstanding securities. Analyzing the company's total market value allows for a comparison of the business scale with the commercial success of the Neffy nasal spray, where patent protection and high demand determine the asset's resilience within the fast-growing biotechnology class.

Key competitors